PMA supplement

P010031 S303: CONCERTO II CRT-D, CONSULTA & DF4, MAXIMO II CRT-D & DF4, PROTECTA CRT-D & DF4 & XT CRT-D & XT DF4

FDA PMA supplement · 30-Day Notice · Medtronic Cardiac Rhythm Disease Management

Key facts

Original PMA P010031
Supplement number S303
Supplement type 30-Day Notice
Reason for the supplement Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name CONCERTO II CRT-D, CONSULTA & DF4, MAXIMO II CRT-D & DF4, PROTECTA CRT-D & DF4 & XT CRT-D & XT DF4
Applicant Medtronic Cardiac Rhythm Disease Management
Received date Apr 25, 2012
Decision date May 23, 2012

At a glance

  • No Expedited review granted
  • No Approval order on file
  • No Summary of safety and effectiveness on file

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMA supplements

A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.

Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date:

Browse all PMA supplements